Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 1Lymphoma 1Carcinoma 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × patritumab × Clear all
NCT01479023 2013-12-20

Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
12 enrolled
LymphoidSarcoma

Carcinoma, Lymphoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡